GHRL and neoplasm: The second line of support is provided by the direct association of In1-ghrelin, GHSR1b and GOAT expression levels —but not of native-ghrelin and GHSR1a— with a worse clinical outcome, i.e. tumors of patients with progressive disease have higher levels of these components vs. patients with complete remission of the tumor.